CDTX - Cidara Therapeutics Inc. (CDTX) Investigation: Bronstein Gewirtz & Grossman LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cidara Therapeutics, Inc. ("Cidara" or "the Company") (NASDAQ:CDTX). Investors who purchased Cidara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDTX.

Investigation Details:

On April 16, 2024, Cidara filed a current report on Form 8-K with the SEC and announced that it's "previously issued audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2022 included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and each of the Company's previously issued unaudited condensed consolidated financial statements included in the Company's Quarterly Reports on Form 10-Q for each of the quarterly periods in 2022 and 2023 (collectively, the "Prior Financial Statements") filed with the [SEC] should no longer be relied upon and should be restated[.]" Cidara also said that its management had "concluded that the Company's disclosure controls and procedures were not effective at the reasonable assurance level and the Company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement." Following this news, Cidara stock dropped $1.89 per share, or 11.5%, to close at $14.60 on April 16, 2024.

What's Next?

If you are aware of any facts relating to this investigation or purchased Cidara securities, you can assist this investigation by visiting the firm's site: bgandg.com/CDTX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC